Hiromatsu Yuji
Division of Endocrinology and Metabolism, Department of Medicine, Kurume University School of Medicine.
Nihon Rinsho. 2006 Dec;64(12):2279-85.
Glucocorticoids are usually given for management of Graves' ophthalmopathy (GO) for their anti-inflammatory and immunosuppressive effects. The overall rate of favorable response for moderately severe and active GO is 77% in patients treated with methylprednisolone iv pulse therapy. When radioiodine therapy is indicated for hyperthyroidism in Graves' patients with high risk factors, the use of glucocorticoid with small doses and short periods is recommended to prevent the development or progression of GO. Cushingoid features, glucose intolerance, gastritis, hypertension, hepatitis, and depression are major adverse effects of glucocorticoids. Fatal liver failure after high dose of pulse therapy (9-12g) was observed in 0.8%. Limiting the cumulative dose to 4.5-6g, assessment of liver virus markers and monitoring liver function before, during and after i.v. treatment are warranted.
糖皮质激素通常因其抗炎和免疫抑制作用而用于治疗格雷夫斯眼病(GO)。接受甲泼尼龙静脉脉冲治疗的中度至重度活动性GO患者的总体良好反应率为77%。当对有高风险因素的格雷夫斯病甲亢患者进行放射性碘治疗时,建议使用小剂量、短疗程的糖皮质激素以预防GO的发生或进展。库欣样特征、葡萄糖不耐受、胃炎、高血压、肝炎和抑郁是糖皮质激素的主要不良反应。高剂量脉冲治疗(9 - 12g)后观察到0.8%的患者出现致命性肝衰竭。将累积剂量限制在4.5 - 6g,在静脉治疗前、治疗期间和治疗后评估肝脏病毒标志物并监测肝功能是必要的。